NCT05418088View on ClinicalTrials.gov

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2026

Conditions
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent High Grade B-Cell LymphomaRecurrent Indolent Non-Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory B-Cell Prolymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory High Grade B-Cell LymphomaRefractory Indolent Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRefactory Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Anti-CD19/CD20/CD22 CAR T-Cells

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Pheresis

Undergo apheresis

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (2)

43203

RECRUITING

Nationwide Children's Hospital, Columbus

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sumithira Vasu

OTHER